Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June 23, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a therapeutic, today announced that it has…


Previous articlePT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women, Coaching, and Ketamine For Fibromyalgia
Next articleDiamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin